BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 954 filers reported holding BAXTER INTL INC in Q1 2014. The put-call ratio across all filers is 0.58 and the average weighting 0.5%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $35,000 | -28.6% | 540 | -31.6% | 0.02% | -36.8% |
| Q3 2017 | $49,000 | -18.3% | 790 | -20.2% | 0.04% | -11.6% |
| Q2 2017 | $60,000 | -17.8% | 990 | -29.3% | 0.04% | -17.3% |
| Q1 2017 | $73,000 | -98.3% | 1,400 | -97.7% | 0.05% | -97.6% |
| Q3 2014 | $4,356,000 | -1.3% | 60,600 | 0.0% | 2.14% | +6.0% |
| Q2 2014 | $4,413,000 | -0.0% | 60,600 | 0.0% | 2.02% | -1.2% |
| Q1 2014 | $4,415,000 | +13.5% | 60,600 | +8.0% | 2.05% | +22.1% |
| Q4 2013 | $3,889,000 | +12.2% | 56,100 | +7.5% | 1.68% | +1.2% |
| Q3 2013 | $3,465,000 | -4.8% | 52,200 | 0.0% | 1.66% | +7.4% |
| Q2 2013 | $3,638,000 | – | 52,200 | – | 1.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tavio Capital LLC | 68,405 | $5,890,000 | 7.81% |
| Iron Triangle Partners LP | 330,000 | $28,413,000 | 7.16% |
| Veritas Asset Management LLP | 8,942,428 | $769,943,000 | 5.64% |
| TSFG, LLC | 93,405 | $8,042,000 | 5.31% |
| GENERATION INVESTMENT MANAGEMENT LLP | 10,606,094 | $913,185,000 | 5.27% |
| Third Point | 4,000,000 | $344,400,000 | 4.72% |
| Avidity Partners Management LP | 800,900 | $68,957,000 | 4.42% |
| Palmer Knight Co | 62,275 | $5,362,000 | 4.17% |
| Eos Focused Equity Management, L.P. | 36,786 | $3,167,000 | 3.70% |
| Dundas Partners LLP | 196,133 | $16,887,000 | 3.69% |